{"id":"W2944392072","doi":"10.1186/s40425-019-0541-0","title":"An interim report on the investigator-initiated phase 2 study of pembrolizumab immunological response evaluation (INSPIRE)","year":2019,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":true,"ca_institutions":"Vector Institute; Institute of Cancer Research; Ontario Institute for Cancer Research; University Health Network; University of Toronto; Princess Margaret Cancer Centre","funders":"Terry Fox Research Institute; Ontario Ministry of Research, Innovation and Science; Canada Research Chairs; Government of Ontario; Ontario Institute for Cancer Research; Ontario Ministry of Research and Innovation; Princess Margaret Cancer Foundation","keywords":"Pembrolizumab; Medicine; Internal medicine; Immunophenotyping; Oncology; Immune system; CD8; Tumor-infiltrating lymphocytes; Interim analysis; Clinical trial; Immunotherapy; Immunology; Antigen","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008429753,0.001187985,0.001177097,0.0003783944,0.000700811,0.001832632,0.001617999,0.002775869,0.03401618],"category_scores_gemma":[0.005597898,0.0004450835,0.0008819199,0.0004100956,0.0002642419,0.0009075501,0.0007516622,0.002442893,0.01005887],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008465133,"about_ca_system_score_gemma":0.002900181,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006991486,"about_ca_topic_score_gemma":0.001542003,"domain_scores_codex":[0.9975783,0.0009737321,0.0001885866,0.0002624691,0.0006889948,0.0003078932],"domain_scores_gemma":[0.9946594,0.001022113,0.0006764598,0.0003591924,0.00143013,0.001852802],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.08538035,0.009574292,0.008742911,0.001839987,0.001401836,0.00080523,0.0001473809,0.001154358,0.01564971,0.001868414,0.6696813,0.2037542],"study_design_scores_gemma":[0.100785,0.08921354,0.04408156,0.0006526106,0.001333479,0.001361193,0.0001013091,0.003159185,0.01053979,0.002990128,0.745666,0.0001161847],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"dataset","genre_gemma":"empirical","genre_scores_codex":[0.1815353,0.03496332,0.04015115,0.05661901,0.04524094,0.08980184,0.305292,0.002672701,0.2437239],"genre_scores_gemma":[0.3207528,0.01650641,0.03436469,0.05036196,0.02142015,0.05789392,0.2121124,0.001118692,0.2854691],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.03401618,"threshold_uncertainty_score":0.1137955,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1028992372457835,"score_gpt":0.4450525707470737,"score_spread":0.3421533335012902,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}